CO-PROMETHEUS-MATERIALS
12.1.2023 14:01:40 CET | Business Wire | Press release
Prometheus Materials, a leader in sustainable building materials, today announced the appointment of Vishaan Chakrabarti, FAIA FRAIC, to its Board of Directors. Chakrabarti joins a dedicated leadership team working to harness Prometheus Materials’ technology to accelerate the world’s transition to a carbon-negative future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005190/en/
Vishaan Chakrabarti, FAIA FRAIC – Founder and Creative Director of Practice for Architecture and Urbanism (PAU) – joins the Prometheus Materials Board of Directors. (Photo: Business Wire)
This Board addition comes on the heels of multiple company milestones. In June 2022, Prometheus Materials announced its $8 Million Series A Funding Round led by Paris-based VC firm Sofinnova Partners, with participation by the Microsoft Climate Innovation Fund, Skidmore, Owings & Merrill (SOM), GAF, and The Autodesk Foundation. In July 2022, Prometheus Materials and SOM announced a partnership to ultimately develop zero-carbon building materials.
“We are thrilled to welcome Vishaan to our board,” said Loren Burnett, President and CEO of Prometheus Materials. “Vishaan has unique expertise to help guide the company through new levels of growth – conducting key advocacy work in the market at-large to promote sustainable legislation, helping to drive critical industry connections, and addressing market awareness and acceptance around the benefits of sustainable building materials.”
Chakrabarti brings a wealth of experience to his new role, in which he has acutely focused on sustainable design. He is the Founder and Creative Director of Practice for Architecture & Urbanism (PAU), a design firm dedicated to lasting architecture and human urbanism to advance healthy cities. Previously, he served as Director of Planning for Manhattan, assisting in the reconstruction of the new World Trade Center and the design of New York City’s High Line and 7 Line expansion, among other projects. He also served as Dean at the University of California - Berkeley College of Environmental Design, and has given main stage TED Talks on sustainability in architecture and urban design.
“Joining Prometheus Materials’ board feels like a natural extension of the mission of my life’s work,” said Chakrabarti. “There will be an avalanche of growth in the demand for sustainable building materials in the coming years and Prometheus Materials’ technology is vital in addressing a key polluting sector. Concrete is one of the world’s primary building materials and I’m honored to work with this team to help change the status quo of urban design through sustainable materials.”
Cement production accounts for 8% of annual CO2 emissions and consumes 9% of annual industrial water production on a global basis. In contrast to traditional portland-based cement, the production of Prometheus Materials' microalgae-based building materials emits little-to-no CO2 and recycles 95% of the water used.
About Prometheus Materials
Prometheus Materials provides sustainable building materials that accelerate the world’s transition to a carbon-negative future. Inspired by biological processes found in nature, the company's process uses microalgae to produce a bio-cement that offers an alternative to carbon-intensive portland cement. When mixed with aggregate, this bio-cement forms an ultra low-carbon bio-concrete with mechanical, physical, and thermal properties that rival those of portland cement-based concrete. Learn more about how the company enables the decarbonization of the construction industry at prometheusmaterials.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005190/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom